A multicomponent IOL system featuring an exchangeable front optic (PreciSight Lens, InfiniteVision Optics, Strasbourg, France) is showing promise for providing a reliable, reproducible, safe, simple, and time-independent solution for achieving desired refractive outcomes after cataract surgery, said Harvey S. Uy, MD.
Outcomes in a series of 30 eyes that underwent exchange of the front optic to correct dioptric power showed the procedure was safe and effective. Prior to enhancement, all patients had MRSE >1 D (mean 1.06 D) and < -1.0 D cylinder (mean -0.30 D). Mean logMAR distance uncorrected visual acuity (UDVA) prior to the enhancement was 0.19 (about 20/30 Snellen equivalent).
Analyses of data available from 30 eyes seen at 3 months post-enhancement showed statistically significant improvements in both mean MRSE (0.31 D) and mean logMAR UDVA of 0.02 (about 20/20 Snellen equivalent). There was no statistically significant change in mean cylinder. Furthermore, at 3 months, 100% of eyes had UDVA of 20/25 or better.
Additional measurements showed that the system exhibited excellent rotational stability; anterior chamber depth was unchanged after the exchange, indicating implant stability; and endothelial cell count was also unchanged. No other safety issues were observed, said Dr. Uy, clinical associate professor of ophthalmology, University of the Philippines, and medical director, Peregrine Eye and Laser Institute in Makati, Philippines.
Dr. Uy receives research funding from InfiniteVision Optics and from ClarVista Medical, which is developing another multicomponent IOL (Harmoni Modular IOL).